| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28b0cca481a14a26522db52d3dbda170 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-3337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-0266
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M39-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-465 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F13-00 |
| filingDate |
2005-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f70f1e5018b01564186ece7addeb7be4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d0919fec6e464e322015254e15b69d2 |
| publicationDate |
2007-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1802258-A2 |
| titleOfInvention |
Biosynchronous transdermal drug delivery |
| abstract |
A delivery mechanism and device for the passive periodic release of a drug or an active ingredient and the methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms. This strategy is intended to counteract disease states and symptoms when they are likely to be at their worst by using an automated and pre-programmable transdermal or other drug administration system. |
| priorityDate |
2004-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |